Header Logo

Connection

SANJAY MATHEW to Antidepressive Agents

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Antidepressive Agents.
SANJAY MATHEW
Connection Strength
9.345
Antidepressive Agents
  1. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology. 2024 Jan; 49(1):189-196.
    View in: PubMed
    Score: 0.715
  2. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.615
  3. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
    View in: PubMed
    Score: 0.467
  4. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
    View in: PubMed
    Score: 0.461
  5. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81.
    View in: PubMed
    Score: 0.416
  6. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015 Mar; 29(3):181-8.
    View in: PubMed
    Score: 0.400
  7. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1.
    View in: PubMed
    Score: 0.366
  8. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.362
  9. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012 Oct 01; 72(7):537-47.
    View in: PubMed
    Score: 0.331
  10. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 Feb; 166(2):140-5.
    View in: PubMed
    Score: 0.262
  11. Anxiety and depression: leading edge of therapy. Mt Sinai J Med. 2008 May-Jun; 75(3):171-3.
    View in: PubMed
    Score: 0.249
  12. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92.
    View in: PubMed
    Score: 0.243
  13. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8.
    View in: PubMed
    Score: 0.208
  14. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e2514278.
    View in: PubMed
    Score: 0.202
  15. Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression. J Psychopathol Clin Sci. 2025 Apr; 134(3):228-238.
    View in: PubMed
    Score: 0.194
  16. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
    View in: PubMed
    Score: 0.189
  17. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
    View in: PubMed
    Score: 0.187
  18. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325.
    View in: PubMed
    Score: 0.177
  19. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
    View in: PubMed
    Score: 0.176
  20. Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275.
    View in: PubMed
    Score: 0.175
  21. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.170
  22. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opin Drug Saf. 2022 Jun; 21(6):745-759.
    View in: PubMed
    Score: 0.163
  23. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4).
    View in: PubMed
    Score: 0.155
  24. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.152
  25. Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression? Am J Psychiatry. 2020 10 01; 177(10):891-894.
    View in: PubMed
    Score: 0.147
  26. Ketamine for depression clinical issues. Adv Pharmacol. 2020; 89:131-162.
    View in: PubMed
    Score: 0.142
  27. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.135
  28. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238.
    View in: PubMed
    Score: 0.131
  29. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.131
  30. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
    View in: PubMed
    Score: 0.130
  31. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
    View in: PubMed
    Score: 0.130
  32. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.128
  33. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.127
  34. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.112
  35. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.100
  36. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.099
  37. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.096
  38. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6.
    View in: PubMed
    Score: 0.084
  39. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204.
    View in: PubMed
    Score: 0.081
  40. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70.
    View in: PubMed
    Score: 0.081
  41. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5.
    View in: PubMed
    Score: 0.076
  42. Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. J Clin Psychiatry. 2024 Nov 25; 85(4).
    View in: PubMed
    Score: 0.049
  43. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902.
    View in: PubMed
    Score: 0.046
  44. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475.
    View in: PubMed
    Score: 0.046
  45. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
    View in: PubMed
    Score: 0.043
  46. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
    View in: PubMed
    Score: 0.043
  47. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
    View in: PubMed
    Score: 0.042
  48. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112.
    View in: PubMed
    Score: 0.042
  49. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
    View in: PubMed
    Score: 0.036
  50. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93.
    View in: PubMed
    Score: 0.018
  51. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009 Feb 03; 180(3):305-13.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.